Functional Genetics, Inc.
11Patents
8Active
11Granted
44Portfolio score
Filing activity: Nov 12, 1997 → May 11, 2010 · 8 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5922617A | Rapid screening assay methods and devices | Emerging Cross-Sectional Technologies | 243 | Expired |
| US7427468B2 | Anti-TSG101 antibodies and their uses for treatment of viral infections | Emerging Cross-Sectional Technologies | 5 | Expired |
| US8476009B2 | Methods for detecting enveloped virus infections by measuring cell surface TSG101 | Emerging Cross-Sectional Technologies | 2 | Active |
| US7494767B2 | Assay for TSG101 as inhibitors of HIV production | Physics | 1 | Expired |
| US8021833B2 | Method for reducing HIV viral budding by administering a VPS28-specfic antibody that disrupts Gag-TSG101-VPS28 binding interactions | Physics | 1 | Active |
| US7981410B2 | Therapeutic targeting of escort proteins | Human Necessities | 1 | Active |
| US8182985B2 | Anti-TSG101 antibodies and their uses for treatment of viral infections | Emerging Cross-Sectional Technologies | 1 | Active |
| US7745148B2 | Random homozygous gene perturbation to enhance antibody production | Chemistry; Metallurgy | 1 | Active |
| US8361792B2 | Random homozygous gene perturbation to enhance antibody production | Chemistry; Metallurgy | 0 | Active |
| US8535684B2 | Methods of inhibiting HIV infectivity | Chemistry; Metallurgy | 0 | Active |
| US8207209B2 | Methods of inhibiting viral infection | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.